Journal of Thrombosis and Thrombolysis

, Volume 37, Issue 3, pp 372–379 | Cite as

Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians

Article

Abstract

Vitamin K antagonists have been the only available oral anticoagulant therapy for decades until the recent introduction of novel (new) oral anticoagulants. This breakthrough provides patients with alternative treatment choices that have predictable pharmacokinetics and do not require routine coagulation monitoring. Though more convenient from patient perspective, these drugs have distinct pharmacological properties that are particularly important to recognize when transitioning anticoagulant therapies. The following review focuses on transitioning to and from the novel oral anticoagulants, employing a practical pharmacokinetic- and pharmacodynamic-based approach.

Keywords

Oral anticoagulants Transitions of anticoagulants Dabigatran Rivaroxaban Apixaban Edoxaban 

Abbreviations

NOAC

Novel oral anticoagulants

VKA

Vitamin K antagonists

VTE

Venous thromboembolism

AF

Atrial fibrillation

UFH

Unfractionated heparin

LMWH

Low molecular weight heparin

INR

International normalized ratio

aPTT

Activated partial thromboplastin time

P-gp

P-glycoprotein

GFR

Glomerular filtration rate

References

  1. 1.
    Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167(13):1414–1419. doi: 10.1001/archinte.167.13.1414 PubMedCrossRefGoogle Scholar
  2. 2.
    Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ (2013) Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services. Am J Cardiol 112(3):387–389. doi: 10.1016/j.amjcard.2013.03.046 PubMedCrossRefGoogle Scholar
  3. 3.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, RA Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891. doi: 10.1056/NEJMoa1009638 PubMedCrossRefGoogle Scholar
  4. 4.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, A Committees Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992. doi: 10.1056/NEJMoa1107039 PubMedCrossRefGoogle Scholar
  5. 5.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, R-LS Committee Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. doi: 10.1056/NEJMoa0905561 PubMedCrossRefGoogle Scholar
  6. 6.
    Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415. doi: 10.1056/NEJMoa1306638 CrossRefGoogle Scholar
  7. 7.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2013) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. doi: 10.1016/S0140-6736(13)62343-0 PubMedGoogle Scholar
  8. 8.
    Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, R-CS Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352. doi: 10.1056/NEJMoa0906598 PubMedCrossRefGoogle Scholar
  9. 9.
    E Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi: 10.1056/NEJMoa1007903 PubMedCrossRefGoogle Scholar
  10. 10.
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, A Investigators (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808. doi: 10.1056/NEJMoa1302507 PubMedCrossRefGoogle Scholar
  11. 11.
    Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, R-A Investigators (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369(13):1206–1214. doi: 10.1056/NEJMoa1300615 PubMedCrossRefGoogle Scholar
  12. 12.
    Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC (2013) Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke; A J Cereb Circul 44(6):1676–1681. doi: 10.1161/STROKEAHA.111.000402 CrossRefGoogle Scholar
  13. 13.
    Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S (2013) The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 128(3):237–243. doi: 10.1161/CIRCULATIONAHA.112.001139 PubMedCrossRefGoogle Scholar
  14. 14.
    Mahaffey KW, Hellkamp AS, Patel MR, Hannan KL, Schwabe K, Nessel CC, Berkowitz SD, Halperin JL, Hankey GJ, Becker RC, Piccini JP, Breithardt G, Hacke W, Singer DE, Califf RM, Fox KA (2013) End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circul Cardiovasc Qual Outcomes 6(4):470–478. doi: 10.1161/CIRCOUTCOMES.113.000132 CrossRefGoogle Scholar
  15. 15.
    Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW (2013) Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 61(6):651–658. doi: 10.1016/j.jacc.2012.09.057 PubMedCrossRefGoogle Scholar
  16. 16.
    Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, Hylek E, Ansell JE, Wallentin L (2012) Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. Eur Heart J 33(suppl 1):685–686Google Scholar
  17. 17.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, EA-T Investigators (2013) Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104. doi: 10.1056/NEJMoa1310907 PubMedCrossRefGoogle Scholar
  18. 18.
    Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY (2012) Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 60(9):861–867. doi: 10.1016/j.jacc.2012.06.019 PubMedCrossRefGoogle Scholar
  19. 19.
    Adcock DM, Gosselin R, Kitchen S, Dwyre DM (2013) The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 139(1):102–109. doi: 10.1309/AJCPY6G6ZITVKPVH PubMedCrossRefGoogle Scholar
  20. 20.
    Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 59(5):807–814. doi: 10.1373/clinchem.2012.198788 PubMedCrossRefGoogle Scholar
  21. 21.
    van Ryn J, Baruch L, Clemens A (2012) Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 125(4):417–420. doi: 10.1016/j.amjmed.2011.10.017 PubMedCrossRefGoogle Scholar
  22. 22.
    Harenberg J, Erdle S, Marx S, Kramer R (2012) Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 38(2):178–184. doi: 10.1055/s-0032-1301415 PubMedCrossRefGoogle Scholar
  23. 23.
    Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743–753. doi: 10.1177/0091270009351883 PubMedCrossRefGoogle Scholar
  24. 24.
    Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F (2013) Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75(2):476–487. doi: 10.1111/j.1365-2125.2012.04369.x PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Mendell J, Noveck RJ, Shi M (2013) A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol 75(4):966–978. doi: 10.1111/j.1365-2125.2012.04409.x PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F (2013) Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 110(2):283–294. doi: 10.1160/TH12-12-0898 PubMedCrossRefGoogle Scholar
  27. 27.
    Stangier J, Stahle H, Rathgen K, Roth W, Reseski K, Kornicke T (2011) Pharmacokinetics and pharmacodynamics of Dabigatran Etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol. doi: 10.1177/0091270010393342
  28. 28.
    Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51(7):549–561. doi: 10.5414/CP201812 PubMedCrossRefGoogle Scholar
  29. 29.
    Mueck W, Stampfuss J, Kubitza D, Becka M (2013) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. doi: 10.1007/s40262-013-0100-7 PubMedCentralGoogle Scholar
  30. 30.
    Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L, A Investigators (2010) Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159(3):331–339. doi: 10.1016/j.ahj.2009.07.035 PubMedCrossRefGoogle Scholar
  31. 31.
    Mendell J, Noveck RJ, Shi M (2012) Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol 60(4):335–341. doi: 10.1097/FJC.0b013e31826265b6 PubMedCrossRefGoogle Scholar
  32. 32.
    Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C (2012) A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost 107(5):916–924. doi: 10.1160/TH11-09-0634 PubMedCrossRefGoogle Scholar
  33. 33.
    Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M, Hartter S (2012) Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol 68(5):607–616. doi: 10.1007/s00228-011-1205-2 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Cardiovascular Health and Disease, University of Cincinnati College of MedicineUniversity of CincinnatiCincinnatiUSA

Personalised recommendations